EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options to two new employees as part of an inducement award. On January 13, 2023, the company approved stock options for a total of 4,000 shares, each with an exercise price of $5.04, reflecting the stock's closing price on that date. These options vest over four years, with an initial 25% vesting after one year and the remainder in monthly installments. This move aligns with NASDAQ Listing Rule 5635(c)(4) and aims to attract talented personnel to support EyePoint's commitment to developing therapeutics for serious eye disorders.
AI-generated analysis. Not financial advice.
Positive
- Granting stock options may enhance employee retention and motivation.
- The exercise price of $5.04 is aligned with the market rate, indicating sound decision-making in compensation.
Negative
- None.
News Market Reaction – EYPT
On the day this news was published, EYPT declined 10.91%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 4,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on January 13, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
For EyePoint Pharmaceuticals:
Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
